These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26953243)

  • 1. Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment.
    Dreesen E; Gils A; Vermeire S
    Curr Drug Targets; 2018; 19(7):757-776. PubMed ID: 26953243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?
    Strik AS; Wang YC; Ruff LE; Yashar W; Messmer BT; Mould DR
    AAPS J; 2018 Sep; 20(6):99. PubMed ID: 30187153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine.
    Lefevre PLC; Shackelton LM; Vande Casteele N
    BioDrugs; 2019 Oct; 33(5):453-468. PubMed ID: 31301024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
    Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
    Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies.
    Steenholdt C
    Dan Med J; 2016 Aug; 63(8):. PubMed ID: 27477799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling.
    Passot C; Pouw MF; Mulleman D; Bejan-Angoulvant T; Paintaud G; Dreesen E; Ternant D
    Ther Drug Monit; 2017 Aug; 39(4):322-326. PubMed ID: 28703717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
    Hoseyni H; Xu Y; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug monitoring of biologics in inflammatory bowel disease.
    Eser A; Primas C; Reinisch W
    Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
    Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
    Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease.
    Sheasgreen C; Nguyen GC
    Curr Gastroenterol Rep; 2017 May; 19(5):19. PubMed ID: 28397129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
    Van den Berghe N; Gils A; Thomas D
    Clin Pharmacol Ther; 2019 Nov; 106(5):945-954. PubMed ID: 31420861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?
    Strik AS; Berends SE; Löwenberg M
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):885-891. PubMed ID: 31305158
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
    Franca R; Curci D; Lucafò M; Decorti G; Stocco G
    Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):527-539. PubMed ID: 31177858
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
    Papamichael K; Cheifetz AS
    Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.
    Vande Casteele N; Herfarth H; Katz J; Falck-Ytter Y; Singh S
    Gastroenterology; 2017 Sep; 153(3):835-857.e6. PubMed ID: 28774547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.
    Ordás I; Feagan BG; Sandborn WJ
    Clin Gastroenterol Hepatol; 2012 Oct; 10(10):1079-87; quiz e85-6. PubMed ID: 22813440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring in inflammatory bowel disease treatments.
    Wang MY; Zhao JW; Zheng CQ; Sang LX
    World J Gastroenterol; 2022 Apr; 28(15):1604-1607. PubMed ID: 35582129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
    Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
    AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.